All In Biotech

Drug Trial Radar · NCT00796367

A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787)

A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Extension Study (From Study OB-303 [NCT00553787]) to Determine the Safety and Efficacy Of VI-0521 for the Long-Term Treatment Of Obesity in Adults With Obesity-Related Co-Morbid Conditions.

Last checked: Nov 20, 2026Latest source record: Sep 10, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 676 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

676

Actual

Start

Dec 2008

Primary completion

Jun 2010

Study completion Jul 2010

Sponsor

Lead sponsor
VIVUS LLCIndustry
Sponsor type
Industry
Collaborators
Medpace, Inc.
First posted
Nov 24, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the long-term safety and efficacy of VI-0521 compared to placebo for the treatment of overweight and obesity in adults who have completed study OB-303 (NCT00553787) at selected study sites. This is an extension study of protocol OB-303 (NCT00553787).

Conditions

  • Obesity

Interventions

  • VI-0521Drug

    7.5 mg phentermine and 46 mg topiramate

  • PlaceboDrug

    placebo

  • VI-0521Drug

    15 mg phentermine and 92 mg topiramate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Weight Change at End of Treatment, Week 108.Time frame: From baseline to end of treatment
  2. Percentage of Subjects With at Least 5% Weight Loss at End of Treatment, Week 108.Time frame: Baseline to End of Treatment

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.